GlassScriptPhysician profile
Lindsay S Gonzalez
NPI 1538481601
$5,093.90
in general payments reported to CMS, 2019-2025
31 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $979 · 2022: $967 · 2023: $915 · 2024: $906 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,065 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.71 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $958.99 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $786.39 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $743.55 | 2021-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.79 | 2021-2025 | Jardiance |
| Abbvie INC. | $297.32 | 2021-2025 | |
| Janssen Biotech, INC. | $296.38 | 2025 | Tremfya |
| Exact Sciences Corporation | $156.53 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $126.03 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $118.80 | 2021-2023 | |
| Ardelyx, INC. | $118.71 | 2025 | Ibsrela |
| Abbott Laboratories | $114.24 | 2022-2025 | Freestyle Libre 3, Octrode |
| Merck Sharp & Dohme LLC | $101.29 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.33 | 2025 | Entyvio, Eohilia |
| Pfizer INC. | $87.34 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $86.08 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.17 | 2024-2025 | Xifaxan, Trulance |
| Actelion Pharmaceuticals US, INC. | $75.54 | 2023-2024 | Opsumit |
| Biohaven Pharmaceuticals, INC. | $71.24 | 2021 | |
| Genzyme Corporation | $69.54 | 2025 | |
| Glaxosmithkline, LLC. | $63.61 | 2023-2024 | Shingrix, Arexvy |
| Celltrion USA INC. | $55.59 | 2025 | Vegzelma |
| Amgen INC. | $49.26 | 2023-2025 | Otezla, Repatha, Otezla |
| Qol Medical, LLC | $35.84 | 2025 | Sucraid |
| Sanofi Pasteur INC. | $29.41 | 2023 | |
| Horizon Therapeutics Plc | $26.93 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $25.04 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $22.96 | 2025 | Dupixent |
| Vertex Pharmaceuticals Incorporated | $21.36 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.08 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.33 | 2025 | Voquezna |
| Watermark Medical, INC. | $16.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.